. 2020 May 14;11(3):98–105. doi: 10.14740/wjon1275

Table 3. Baseline Characteristics, Treatment and Laboratory Data According to RMH Score.

	RMH score		P
	Low	High	P
N	54	74
Backgrounds
Sex (N)
Male/female	45/9	56/18	0.38^a
Age (years)
Median (IQR)	72 (66 - 76)	71.5 (65.3 - 80)	0.83^b
< 75/≥ 75 years	33/21	46/28	1.00^a
Smoking status (N)
NS/Ex/CS/unknown	1/19/34/0	2/22/49/1	0.93^a
BMI
Median (IQR)	22.8 (19.8 - 26.1)	21.3 (19.4 - 24.3)	0.22^b
≥ 18.5/< 18.5 (N)	49/5	63/11	0.42^a
ECOG-PS (N)
0 - 1/2/3	39/13/2	38/18/18	< 0.01^a
Metastatic sites (N)
< 3/≥ 3	47/7	18/56	< 0.01^a
Treatment
Regimen (N)
Platinum-based
Cisplatin/carboplatin	12/42	19/55	0.68^a
Partner drugs
Etoposide/irinotecan	46/8	67/7	0.41^a
Efficacy
CR/PR/SD/PD/NE	1/35/10/7/1	1/41/7/14/11	0.04^a
ORR (%) (95% CI)	66.7 (52.5 - 78.9)	56.8 (44.7 - 68.2)	0.27^a
DCR (%) (95% CI)	85.2 (72.9 - 93.4)	66.2 (54.3 - 76.8)	0.02^a
Second or later line (N)	39	30	< 0.01^a
Amrubicin (N)	28	21	< 0.01^a
Topotecan (N)	4	9	0.56^a
Irinotecan (N)	4	3	0.45^a
Radiotherapy
Brain	15	13	0.20^a
Thoracic	5	5	0.74^a
Laboratory data
NLR
Median (IQR)	2.6 (2.0 - 4.0)	4.1 (2.7 - 5.8)	< 0.01^b
> 6 (N)	2	19	< 0.01^a
LDH (U/L)
Median (IQR)	212 (186 - 314)	332 (266 - 490)	< 0.01^b
> ULN (N)	23	68	< 0.01^a
Albumin (g/dL)
Median (IQR)	3.9 (3.7 - 4.1)	3.3 (2.8 - 3.8)	<0.01^b
< 3.5 g/dL (N)	7	47	<0.01^a

^aFisher exact test. ^bMann-Whitney U test. BMI: body mass index; CI: confidence interval; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group performance status; Ex: ex-smoker; IQR: interquartile range; LDH: lactate dehydrogenase; NE: not evaluated; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; PD: progressive disease; RMH score: Royal Marsden Hospital prognostic score; SD: stable disease; ULN: upper limit of normal.